To include your compound in the COVID-19 Resource Center, submit it here.

Nov. 11 SITC Roundup: Celyad's first clinical data for allogeneic CAR Ts, plus Vaccibody and Nektar

Celyad reports no GvHD, two PRs in allogeneic CAR T trial
Newly presented data from a Phase I trial of an allogeneic CAR T from Celyad S.A. (Euronext:CYAD; NASDAQ:CYAD) showed that among 12 patients with metastatic colorectal

Read the full 366 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers